Esophagus and Stomach Cancer
EA2183
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients with Esophageal and Gastric Cancer that has Spread to a Limited Number of Other Places in the Body
STATUS: Active
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
- REGISTRATION TO STEP 1
- Patient must be >= 18 years of age
- Patient must have histologically confirmed HER2 negative metastatic esophageal or gastric adenocarcinoma (American Joint Committee on Cancer [AJCC] 8th edition) with known PDL1 CPS expression
- Patient must have oligometastatic disease at the time of diagnosis of metastatic disease and prior to initiation of induction systemic therapy, which is defined as the following: * Once to three (1-3) radiologically visible metastatic lesions (not sites), in addition to the primary site. Computed tomography (CT) or magnetic resonance imaging (MRI) scans will be performed for staging purposes. Patients with oligometastatic sites that are only detected with positron emission tomography (PET)/CT will be eligible for participation, as long as radiation planning and administration is feasible after discussion with treating radiation oncologist. Malignant lymph node must be at least 1 cm in size or biopsy proven involved by disease * Anatomically defined lymphadenopathy will be considered as 1 metastatic lesion. For example, 2 enlarged paraaortic lymph nodes will be considered as one lesion, and 2 additional lesions will be allowed to meet protocol definition of oligometastatic disease. However, if supraclavicular or cervical nodes are involved for distal esophageal tumors or gastric tumors, these are counted separately from intrathoracic nodes. For upper thoracic/cervical esophageal tumors, the involvement of celiac nodes are counted separately from intrathoracic nodes. Intrathoracic nodes, defined as hilar and mediastinal nodes, will be collectively counted as one * Patients with radiologically evident peritoneal metastasis are not eligible.
- Patient must have baseline imaging done within 4 weeks prior to Step 1 registration. For patients registering to Arm S, scans must demonstrate at least stable disease after induction systemic therapy
- Patient must not have any contraindications to 5-fluorouracil (5-FU) capecitabine, leucovorin, or oxaliplatin
- Patients who receive(d) nivolumab in addition to chemotherapy must not have any contraindications to immune check point inhibitors * Patient must not have active autoimmune disease that has required systemic treatment within 2 years prior to Step 1 registration. Patients are permitted to receive immunotherapy if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event) * Patient must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg/day prednisone equivalents) or other immunosuppressive medications within 14 days prior to Step 1 registration. Inhaled or topical steroids and adrenal replacement doses (=< 10 mg/day prednisone equivalent) are permitted * Patients with prior immune mediated adverse events related to immunotherapy that resulted in permanent treatment discontinuation with these agents are ineligible
- Patient must not have any contraindications to radiation therapy based on consultation with a radiation oncologist. Formal radiation oncology evaluation will be required for eligibility purposes. Prior palliative or definitive radiation or chemoradiation to the primary site is allowed. Palliative treatments must be completed at least 2 weeks prior to registration
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patient must not be pregnant or breast-feeding due to the potential harm to unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used * A patient of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 14 days prior to Step 1 registration * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception (both double barrier contraception and birth control pills or implants) or by abstaining from sexual intercourse while on protocol treatment (for all patients) and continue for 5 months after the last dose of protocol treatment (for patients of child bearing potential). Investigators must counsel all patients on the importance of pregnancy prevention and the implications of an unexpected pregnancy
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained within 28 days prior to Step 1 registration)
- Hemoglobin >= 8 g/dL (obtained within 28 days prior to Step 1 registration)
- Platelets (PLT) >= 100 x 10^9/L (obtained within 28 days prior to Step 1 registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (obtained within 28 days prior to Step 1 registration)
- Bilirubin =< 1.5 x institutional ULN (obtained within 28 days prior to Step 1 registration)
- Serum creatinine =< 1.5 x institutional ULN (Cockcroft and Gault formula) (obtained within 28 days prior to Step 1 registration)
- Albumin > 2.5 g/dL (obtained within 28 days prior to Step 1 registration)
- Patient must be able to understand and willing to sign and date the written voluntary informed consent form prior to any protocol-specific procedures. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this protocol and must have CD4 > 200 within 6 months prior to registration *NOTE: HIV testing is not required for eligibility
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this protocol
- Patients who had prior definitive treatment for early stage EGA are eligible for participation as long as recurrent disease developed at least 6 months after completion of all prior therapies
- For patients registering to Arms A, B, G, or H, patient must not have had any systemic prior treatment for metastatic disease * NOTE: Patients previously treated with radiosensitizing doses of 5-FU and oxaliplatin will be eligible for participation as long as adequate time has elapsed from past treatments. If treatments were palliative in nature, 2 week washout is required. For prior definitive treatments with curative intent, recurrent disease must be diagnosed at least 6 months after treatment completion * NOTE: Patients who received systemic chemotherapy as part of the treatment for their locoregional disease (for example, induction therapy before chemoradiation or adjuvant therapy after resection) are eligible for participation, as long as all definitive therapy has been completed at least 6 months prior to Step 1 registration
- For patients registering to Arm S, patient must have completed at least 4 months, but not more than 5 months of systemic induction therapy for advanced disease (with CAPOX, FOLFOX, CAPOX plus nivolumab, or FOLFOX plus nivolumab)
- Any major surgery must have been completed >= 4 weeks prior to Step 1 registration
- Patients with known central nervous system (CNS) metastasis will be excluded from protocol participation, regardless of the status of the CNS disease
- Patient must not have any uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patient must not have had live vaccines within 4 weeks prior to Step 1 registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events)
- REGISTRATION TO STEP 2
- For patients registered to Arms A, B, G or H on Step 1, the patient must have histologically confirmed HER2 negative metastatic esophageal or gastric adenocarcinoma (AJCC 8th edition) with stable disease after 4 cycles of fluorouracil, leucovorin calcium, and oxaliplatin (FOLFOX) or 6 cycles of CAPOX (Step 1 treatment). For patients registered to Arm S on Step 1, patients must have completed at least 4 months, but not more than 5 months of systemic induction therapy for advanced disease (with CAPOX, FOLFOX, CAPOX plus nivolumab, or FOLFOX plus nivolumab)
- Patient must have no evidence of disease progression since systemic induction treatment initiation (all patients on Arms A, B, G, H and S). Imaging must be done within 7 days prior to Step 2 randomization. Patients with complete radiologic response are eligible for Step 2
- Patient must have an ECOG performance status 0-1
- For patients registered to Arms A, B, G or H on Step 1 must have a serum or urine pregnancy test to rule of pregnancy within 14 days prior to Step 2 randomization
United States
AK
Anchorage
Alaska Breast Care and Surgery LLC
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Alaska Oncology and Hematology LLC
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Alaska Women's Cancer Care
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Associates in Radiation Medicine
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Oncology Centre
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Radiation Therapy Center
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Katmai Oncology Group
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Providence Alaska Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
AR
Ft. Smith
Mercy Hospital Fort Smith
Status: ACTIVE
Contact: Site Public Contact
AZ
Kingman
Kingman Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
CA
Arroyo Grande
PCR Oncology
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Burbank
Providence Saint Joseph Medical Center / Disney Family Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: Najee.Boucher@providence.org
Salinas
Salinas Valley Memorial
Status: ACTIVE
Contact: Site Public Contact
Email: tnielsen2@svmh.com
FL
Fort Lauderdale
Holy Cross Hospital
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
IA
Carroll
Saint Anthony Regional Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: sbenson@iora.org
Des Moines
Broadlawns Medical Center
Status: ACTIVE
Contact: Site Public Contact
Iowa Lutheran Hospital
Status: ACTIVE
Contact: Site Public Contact
Iowa Methodist Medical Center
Status: ACTIVE
Contact: Site Public Contact
Medical Oncology and Hematology Associates-Des Moines
Status: ACTIVE
Contact: Site Public Contact
Fort Dodge
Trinity Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
West Des Moines
Methodist West Hospital
Status: ACTIVE
Contact: Site Public Contact
ID
Boise
Saint Alphonsus Cancer Care Center-Boise
Status: ACTIVE
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Luke's Cancer Institute - Boise
Status: ACTIVE
Contact: Site Public Contact
Email: eslinget@slhs.org
Caldwell
Saint Alphonsus Cancer Care Center-Caldwell
Status: ACTIVE
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Coeur D'Alene
Kootenai Health - Coeur d'Alene
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Emmett
Walter Knox Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Fruitland
Saint Luke's Cancer Institute - Fruitland
Status: ACTIVE
Contact: Site Public Contact
Email: eslinget@slhs.org
Meridian
Idaho Urologic Institute-Meridian
Status: ACTIVE
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Luke's Cancer Institute - Meridian
Status: ACTIVE
Contact: Site Public Contact
Email: eslinget@slhs.org
Nampa
Saint Alphonsus Medical Center-Nampa
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Saint Luke's Cancer Institute - Nampa
Status: ACTIVE
Contact: Site Public Contact
Email: eslinget@slhs.org
Post Falls
Kootenai Clinic Cancer Services - Post Falls
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Sandpoint
Kootenai Cancer Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Twin Falls
Saint Luke's Cancer Institute - Twin Falls
Status: ACTIVE
Contact: Site Public Contact
Email: eslinget@slhs.org
IL
Alton
Saint Anthony's Health
Status: ACTIVE
Contact: Site Public Contact
Aurora
Rush - Copley Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: Cancer.Research@rushcopley.com
Bloomington
Illinois CancerCare-Bloomington
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Canton
Illinois CancerCare-Canton
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Carbondale
Memorial Hospital of Carbondale
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.research@sih.net
Carterville
SIH Cancer Institute
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.research@sih.net
Carthage
Illinois CancerCare-Carthage
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Centralia
Centralia Oncology Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Chicago
Northwestern University
Status: ACTIVE
Contact: Site Public Contact
Email: cancer@northwestern.edu
University of Illinois
Status: ACTIVE
Contact: Site Public Contact
Danville
Carle on Vermilion
Status: ACTIVE
Contact: Site Public Contact
Email: Research@carle.com
DeKalb
Northwestern Medicine Cancer Center Kishwaukee
Status: ACTIVE
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Decatur
Cancer Care Specialists of Illinois - Decatur
Status: ACTIVE
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Decatur Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Dixon
Illinois CancerCare-Dixon
Status: ACTIVE
Contact: Site Public Contact
Effingham
Carle Physician Group-Effingham
Status: ACTIVE
Contact: Site Public Contact
Email: Research@carle.com
Crossroads Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Eureka
Illinois CancerCare-Eureka
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Galesburg
Illinois CancerCare-Galesburg
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Western Illinois Cancer Treatment Center
Status: ACTIVE
Contact: Site Public Contact
Geneva
Northwestern Medicine Cancer Center Delnor
Status: ACTIVE
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Homer Glen
Loyola Medicine Homer Glen
Status: ACTIVE
Contact: Site Public Contact
Kewanee
Illinois CancerCare-Kewanee Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Lake Forest
Northwestern Medicine Lake Forest Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrials@northwestern.edu
Macomb
Illinois CancerCare-Macomb
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Mattoon
Carle Physician Group-Mattoon / Charleston
Status: ACTIVE
Contact: Site Public Contact
Email: Research@carle.com
Maywood
Loyola University Medical Center
Status: ACTIVE
Contact: Site Public Contact
Melrose Park
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Mount Vernon
Good Samaritan Regional Health Center
Status: ACTIVE
Contact: Site Public Contact
O'Fallon
Cancer Care Center of O'Fallon
Status: ACTIVE
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Ottawa
Illinois CancerCare-Ottawa Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Pekin
Illinois CancerCare-Pekin
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Peoria
Illinois CancerCare-Peoria
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Methodist Medical Center of Illinois
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
OSF Saint Francis Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Peru
Illinois CancerCare-Peru
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Valley Radiation Oncology
Status: ACTIVE
Contact: Site Public Contact
Princeton
Illinois CancerCare-Princeton
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Springfield
Memorial Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: pallante.beth@mhsil.com
Southern Illinois University School of Medicine
Status: ACTIVE
Contact: Site Public Contact
Springfield Clinic
Status: ACTIVE
Contact: Site Public Contact
Swansea
Southwest Illinois Health Services LLP
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: lynns@thecancercenter.com
Urbana
Carle Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: Research@carle.com
The Carle Foundation Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: Research@carle.com
Warrenville
Northwestern Medicine Cancer Center Warrenville
Status: ACTIVE
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Washington
Illinois CancerCare - Washington
Status: ACTIVE
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Yorkville
Rush-Copley Healthcare Center
Status: ACTIVE
Contact: Site Public Contact
Email: Cancer.Research@rushcopley.com
IN
Richmond
Reid Health
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
KS
Garden City
Central Care Cancer Center - Garden City
Status: ACTIVE
Contact: Site Public Contact
Email: aroland@kccop.org
Great Bend
Central Care Cancer Center - Great Bend
Status: ACTIVE
Contact: Site Public Contact
Email: aroland@kccop.org
MA
Springfield
Mercy Medical Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
ME
Bath
MaineHealth Coastal Cancer Treatment Center
Status: ACTIVE
Contact: Site Public Contact
Email: ctsucontact@westat.com
Biddeford
MaineHealth / SMHC Cancer Care and Blood Disorders-Biddeford
Status: ACTIVE
Contact: Site Public Contact
Email: LLemire@mmc.org
Portland
Maine Medical Center-Bramhall Campus
Status: ACTIVE
Contact: Site Public Contact
Sanford
MaineHealth / SMHC Cancer Care and Blood Disorders-Sanford
Status: ACTIVE
Contact: Site Public Contact
Email: LLemire@mmc.org
MaineHealth Cancer Care Center of York County
Status: ACTIVE
Contact: Site Public Contact
Scarborough
Maine Medical Center- Scarborough Campus
Status: ACTIVE
Contact: Site Public Contact
Email: wrighd@mmc.org
South Portland
Maine Medical Partners - South Portland
Status: ACTIVE
Contact: Site Public Contact
Email: ClinicalResearch@mmc.org
MI
Ann Arbor
Saint Joseph Mercy Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Battle Creek
Bronson Battle Creek
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Bay City
McLaren Cancer Institute-Bay City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Brighton
IHA Hematology Oncology Consultants-Brighton
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Saint Joseph Mercy Brighton
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Canton
IHA Hematology Oncology Consultants-Canton
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Saint Joseph Mercy Canton
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Caro
Caro Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Chelsea
IHA Hematology Oncology Consultants-Chelsea
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Saint Joseph Mercy Chelsea
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Clarkston
Hematology Oncology Consultants-Clarkston
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
McLaren Cancer Institute-Clarkston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Newland Medical Associates-Clarkston
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Detroit
Ascension Saint John Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Wayne State University / Karmanos Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
East China
Great Lakes Cancer Management Specialists-Doctors Park
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Farmington Hills
Weisberg Cancer Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Flint
Genesee Cancer and Blood Disease Treatment Center
Status: ACTIVE
Contact: Site Public Contact
Email: wstrong@ghci.org
Genesee Hematology Oncology PC
Status: ACTIVE
Contact: Site Public Contact
Email: wstrong@ghci.org
Genesys Hurley Cancer Institute
Status: ACTIVE
Contact: Site Public Contact
Email: wstrong@ghci.org
Hurley Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: wstrong@ghci.org
McLaren Cancer Institute-Flint
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Singh and Arora Hematology Oncology PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Grand Rapids
Helen DeVos Children's Hospital at Spectrum Health
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Mercy Health Saint Mary's
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Spectrum Health at Butterworth Campus
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Grosse Pointe Woods
Academic Hematology Oncology Specialists
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Michigan Breast Specialists-Grosse Pointe Woods
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Kalamazoo
Ascension Borgess Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Borgess Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Bronson Methodist Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
West Michigan Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Lansing
Karmanos Cancer Institute at McLaren Greater Lansing
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Mid-Michigan Physicians-Lansing
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Sparrow Hospital
Status: ACTIVE
Contact: Site Public Contact
Lapeer
McLaren Cancer Institute-Lapeer Region
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Livonia
Hope Cancer Clinic
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Mary Mercy Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Macomb Township
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Michigan Breast Specialists-Macomb Township
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Marlette
Saint Mary's Oncology / Hematology Associates of Marlette
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Mount Clemens
McLaren Cancer Institute-Macomb
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Mount Pleasant
McLaren Cancer Institute-Central Michigan
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Muskegon
Mercy Health Mercy Campus
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Niles
Lakeland Hospital Niles
Status: ACTIVE
Contact: Site Public Contact
Norton Shores
Cancer and Hematology Centers of Western Michigan - Norton Shores
Status: ACTIVE
Contact: Site Public Contact
Email: connie.szczepanek@crcwm.org
Novi
Ascension Providence Hospitals - Novi
Status: ACTIVE
Contact: Site Public Contact
Email: karen.fife@ascension.org
Petoskey
McLaren Cancer Institute-Northern Michigan
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Pontiac
21st Century Oncology-Pontiac
Status: ACTIVE
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Hope Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Newland Medical Associates-Pontiac
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Saint Joseph Mercy Oakland
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Port Huron
McLaren-Port Huron
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Reed City
Spectrum Health Reed City Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Rochester Hills
Great Lakes Cancer Management Specialists-Rochester Hills
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saginaw
Ascension Saint Mary's Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Oncology Hematology Associates of Saginaw Valley PC
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Saint Joseph
Lakeland Medical Center Saint Joseph
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Marie Yeager Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Southfield
Ascension Providence Hospitals - Southfield
Status: ACTIVE
Contact: Site Public Contact
Email: karen.fife@ascension.org
Sterling Heights
Bhadresh Nayak MD PC-Sterling Heights
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Tawas City
Ascension Saint Joseph Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Traverse City
Munson Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Warren
Advanced Breast Care Center PLLC
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Great Lakes Cancer Management Specialists-Macomb Professional Building
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Macomb Hematology Oncology PC
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Michigan Breast Specialists-Warren
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
Saint John Macomb-Oakland Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: karen.forman@ascension.org
West Branch
Saint Mary's Oncology / Hematology Associates of West Branch
Status: ACTIVE
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Wyoming
Metro Health Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Ypsilanti
Huron Gastroenterology PC
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
IHA Hematology Oncology Consultants-Ann Arbor
Status: ACTIVE
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
MN
Bemidji
Sanford Joe Lueken Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Burnsville
Fairview Ridges Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Minnesota Oncology - Burnsville
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Cambridge
Cambridge Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Coon Rapids
Mercy Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Edina
Fairview Southdale Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Fridley
Unity Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Maple Grove
Fairview Clinics and Surgery Center Maple Grove
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Maplewood
Minnesota Oncology Hematology PA-Maplewood
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Saint John's Hospital - Healtheast
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Minneapolis
Abbott-Northwestern Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Health Partners Inc
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Hennepin County Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Monticello
Monticello Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
New Ulm
New Ulm Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Princeton
Fairview Northland Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Robbinsdale
North Memorial Medical Health Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Saint Louis Park
Park Nicollet Clinic - Saint Louis Park
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Saint Paul
Regions Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
United Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Shakopee
Saint Francis Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Stillwater
Lakeview Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Thief River Falls
Sanford Thief River Falls Medical Center
Status: ACTIVE
Contact: Site Public Contact
Waconia
Ridgeview Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Willmar
Rice Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Woodbury
Minnesota Oncology Hematology PA-Woodbury
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Worthington
Sanford Cancer Center Worthington
Status: ACTIVE
Contact: Site Public Contact
Wyoming
Fairview Lakes Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
MO
Ballwin
Saint Louis Cancer and Breast Institute-Ballwin
Status: ACTIVE
Contact: Site Public Contact
Bolivar
Central Care Cancer Center - Bolivar
Status: ACTIVE
Contact: Site Public Contact
Email: aroland@kccop.org
Branson
Cox Cancer Center Branson
Status: ACTIVE
Contact: Site Public Contact
Cape Girardeau
Saint Francis Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: sfmc@sfmc.net
Southeast Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Creve Coeur
Siteman Cancer Center at West County Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Farmington
Parkland Health Center - Farmington
Status: ACTIVE
Contact: Site Public Contact
Jefferson City
Capital Region Southwest Campus
Status: ACTIVE
Contact: Site Public Contact
Email: swooden@mail.crmc.org
Joplin
Freeman Health System
Status: ACTIVE
Contact: Site Public Contact
Email: LJCrockett@freemanhealth.com
Mercy Hospital Joplin
Status: ACTIVE
Contact: Site Public Contact
Email: esmeralda.carrillo@mercy.net
Rolla
Delbert Day Cancer Institute at PCRMC
Status: ACTIVE
Contact: Site Public Contact
Email: research@phelpshealth.org
Mercy Clinic-Rolla-Cancer and Hematology
Status: ACTIVE
Contact: Site Public Contact
Saint Joseph
Heartland Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: linda.schumacher@mymlc.com
Saint Louis
Mercy Hospital Saint Louis
Status: ACTIVE
Contact: Site Public Contact
Mercy Hospital South
Status: ACTIVE
Contact: Site Public Contact
Email: janet.lesko@mercy.net
Missouri Baptist Medical Center
Status: ACTIVE
Contact: Site Public Contact
Saint Louis Cancer and Breast Institute-South City
Status: ACTIVE
Contact: Site Public Contact
Siteman Cancer Center at Christian Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Siteman Cancer Center-South County
Status: ACTIVE
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Washington University School of Medicine
Status: ACTIVE
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Saint Peters
Siteman Cancer Center at Saint Peters Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Sainte Genevieve
Sainte Genevieve County Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Springfield
CoxHealth South Hospital
Status: ACTIVE
Contact: Site Public Contact
Mercy Hospital Springfield
Status: ACTIVE
Contact: Site Public Contact
Sullivan
Missouri Baptist Sullivan Hospital
Status: ACTIVE
Contact: Site Public Contact
Sunset Hills
Missouri Baptist Outpatient Center-Sunset Hills
Status: ACTIVE
Contact: Site Public Contact
Washington
Mercy Hospital Washington
Status: ACTIVE
Contact: Site Public Contact
MT
Anaconda
Community Hospital of Anaconda
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Billings
Billings Clinic Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@billingsclinic.org
Bozeman
Bozeman Deaconess Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Great Falls
Benefis Healthcare- Sletten Cancer Institute
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Great Falls Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Kalispell
Kalispell Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Missoula
Community Medical Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Saint Patrick Hospital - Community Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: amy.hanneman@providence.org
ND
Bismarck
Sanford Bismarck Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Fargo
Sanford Broadway Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Sanford Medical Center Fargo
Status: ACTIVE
Contact: Site Public Contact
Sanford Roger Maris Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Sanford South University Medical Center
Status: ACTIVE
Contact: Site Public Contact
Southpointe-Sanford Medical Center Fargo
Status: ACTIVE
Contact: Site Public Contact
NV
Carson City
Carson Tahoe Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Henderson
Cancer and Blood Specialists-Henderson
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Henderson
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Henderson
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Cancer Center-Henderson
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Green Valley
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Pebble
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Seven Hills
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Green Valley
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas
Alliance for Childhood Diseases / Cure 4 the Kids Foundation
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Ann M Wierman MD LTD
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Cancer and Blood Specialists-Shadow
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
Cancer and Blood Specialists-Tenaya
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Central Valley
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Northwest
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Town Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Summerlin
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Desert West Surgery
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Fort Apache
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Las Vegas
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Vegas Tenaya
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology / Hematology-Centennial Hills
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology / Hematology-Maryland Parkway
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology / Hematology-San Martin
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology / Hematology-Tenaya
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org
Hope Cancer Care of Nevada
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Cancer Center-Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Prostate Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Cathedral Rock
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Pecos
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Smoke Ranch
Status: ACTIVE
Contact: Site Public Contact
Email: research@smcrf.org
Las Vegas Urology - Sunset
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Charleston
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Fort Apache
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at MountainView
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Radiation Oncology Centers of Nevada Central
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Radiation Oncology Centers of Nevada Southeast
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Summerlin Hospital Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Sunrise Hospital and Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
University Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
University Medical Center of Southern Nevada
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Central
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Northwest
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Southwest
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Pahrump
Hope Cancer Care of Nevada-Pahrump
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Reno
Radiation Oncology Associates
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Renown Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
Saint Mary's Regional Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@sncrf.org
OH
Beavercreek
Indu and Raj Soin Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Boardman
Saint Elizabeth Boardman Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Centerville
Dayton Physicians LLC-Miami Valley South
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital South
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Cincinnati
Oncology Hematology Care Inc-Kenwood
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Dayton
Dayton Physician LLC-Miami Valley Hospital North
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital North
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Findlay
Armes Family Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Blanchard Valley Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Orion Cancer Care
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Franklin
Atrium Medical Center-Middletown Regional Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Dayton Physicians LLC-Atrium
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Greenville
Dayton Physicians LLC-Wayne
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Wayne Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Kettering
First Dayton Cancer Care
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Greater Dayton Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Kettering Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Springfield
Springfield Regional Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Springfield Regional Medical Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Troy
Dayton Physicians LLC-Upper Valley
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Upper Valley Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Warren
Saint Joseph Warren Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Youngstown
Saint Elizabeth Youngstown Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
OK
Oklahoma City
Mercy Hospital Oklahoma City
Status: ACTIVE
Contact: Site Public Contact
University of Oklahoma Health Sciences Center
Status: ACTIVE
Contact: Site Public Contact
Email: ou-clinical-trials@ouhsc.edu
OR
Baker City
Saint Alphonsus Medical Center-Baker City
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Bend
Saint Charles Health System
Status: ACTIVE
Contact: Site Public Contact
Email: nosall@stcharleshealthcare.org
Clackamas
Clackamas Radiation Oncology Center
Status: ACTIVE
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Providence Cancer Institute Clackamas Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Coos Bay
Bay Area Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: cherie.cox@bayareahospital.org
Newberg
Providence Newberg Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Ontario
Saint Alphonsus Medical Center-Ontario
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Portland
Providence Portland Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Providence Saint Vincent Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Redmond
Saint Charles Health System-Redmond
Status: ACTIVE
Contact: Site Public Contact
PA
Allentown
Lehigh Valley Hospital-Cedar Crest
Status: ACTIVE
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Bethlehem
Lehigh Valley Hospital - Muhlenberg
Status: ACTIVE
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Bryn Mawr
Bryn Mawr Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
Collegeville
Main Line Health Center-Collegeville
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
East Stroudsburg
Pocono Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Exton
Main Line Health Center-Exton
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
Hazleton
Lehigh Valley Hospital-Hazleton
Status: ACTIVE
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Media
Riddle Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
Paoli
Paoli Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
West Reading
Reading Hospital
Status: ACTIVE
Contact: Site Public Contact
Wynnewood
Lankenau Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: turzoe@mlhs.org
SD
Sioux Falls
Sanford Cancer Center Oncology Clinic
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicTrialsSF@sanfordhealth.org
Sanford USD Medical Center - Sioux Falls
Status: ACTIVE
Contact: Site Public Contact
Email: OncologyClinicalTrialsSF@SanfordHealth.org
TN
Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE
Contact: Site Public Contact
TX
Dallas
Parkland Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: canceranswerline@UTSouthwestern.edu
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Contact: Site Public Contact
Email: canceranswerline@UTSouthwestern.edu
UT
Farmington
Farmington Health Center
Status: ACTIVE
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
University of Utah Sugarhouse Health Center
Status: ACTIVE
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
WA
Aberdeen
Providence Regional Cancer System-Aberdeen
Status: ACTIVE
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Bellevue
Overlake Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: OHMCResearch@overlakehospital.org
Bellingham
PeaceHealth Saint Joseph Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: lkey@peacehealth.org
Centralia
Providence Regional Cancer System-Centralia
Status: ACTIVE
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Edmonds
Swedish Cancer Institute-Edmonds
Status: ACTIVE
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Everett
Providence Regional Cancer Partnership
Status: ACTIVE
Contact: Site Public Contact
Email: marilyn.birchman@providence.org
Issaquah
Swedish Cancer Institute-Issaquah
Status: ACTIVE
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Kennewick
Kadlec Clinic Hematology and Oncology
Status: ACTIVE
Contact: Site Public Contact
Email: research@kadlecmed.org
Lacey
Providence Regional Cancer System-Lacey
Status: ACTIVE
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Longview
PeaceHealth Saint John Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: kmakin-bond@peacehealth.org
Renton
Valley Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: research@valleymed.org
Seattle
Pacific Gynecology Specialists
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-Ballard Campus
Status: ACTIVE
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-Cherry Hill
Status: ACTIVE
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-First Hill
Status: ACTIVE
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Sedro-Woolley
PeaceHealth United General Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: lkey@peacehealth.org
Shelton
Providence Regional Cancer System-Shelton
Status: ACTIVE
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Vancouver
PeaceHealth Southwest Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: kmakin-bond@peacehealth.org
Walla Walla
Providence Saint Mary Regional Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: Cheryl.Dodd@providence.org
Yakima
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: Memorial-ClinicalTrials@yvmh.org
Yelm
Providence Regional Cancer System-Yelm
Status: ACTIVE
Contact: Site Public Contact
Email: deidre.dillon@providence.org
WI
Antigo
Langlade Hospital and Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: Juli.Alford@aspirus.org
Eau Claire
HSHS Sacred Heart Hospital
Status: ACTIVE
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Marshfield Medical Center-EC Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Green Bay
Saint Vincent Hospital Cancer Center Green Bay
Status: ACTIVE
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Saint Vincent Hospital Cancer Center at Saint Mary's
Status: ACTIVE
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Johnson Creek
UW Cancer Center Johnson Creek
Status: ACTIVE
Contact: Site Public Contact
Email: lynda.persico@uwmf.wisc.edu
La Crosse
Gundersen Lutheran Medical Center
Status: ACTIVE
Contact: Site Public Contact
Email: cancerctr@gundersenhealth.org
Madison
University of Wisconsin Carbone Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Marshfield
Marshfield Medical Center-Marshfield
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Minocqua
Marshfield Clinic-Minocqua Center
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
New Richmond
Cancer Center of Western Wisconsin
Status: ACTIVE
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Rice Lake
Marshfield Medical Center-Rice Lake
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Stevens Point
Marshfield Clinic Stevens Point Center
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Wausau
Aspirus Regional Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Weston
Marshfield Medical Center - Weston
Status: ACTIVE
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Wisconsin Rapids
Aspirus Cancer Care - Wisconsin Rapids
Status: ACTIVE
Contact: Site Public Contact
WY
Cody
Billings Clinic-Cody
Status: ACTIVE
Contact: Site Public Contact
Email: research@billingsclinic.org
Sheridan
Welch Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
PRIMARY OBJECTIVE: I. Overall survival (OS), which will be measured from the time of randomization. SECONDARY OBJECTIVES: I. Safety and tolerability of consolidative radiation therapy in the treatment of oligometastatic esophageal and gastric adenocarcinoma (EGA). II. Progression-free survival (PFS) which will be measured from the time of randomization. OUTLINE: STEP 1 (INDUCTION PHASE): Patients are assigned to 1 of 5 arms. ARM A: Patients receive oxaliplatin intravenously (IV) over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. ARM G: Patients receive treatment as in Arm A. Patients also receive nivolumab IV on day 1 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. ARM H: Patients receive treatment as in Arm B. Patients also receive nivolumab IV on day one of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. ARM S: Patients who completed induction therapy prior to study enrollment and have no evidence of disease progression are assigned to Arm S and may proceed directly to Step 2 randomization. STEP 2 (CONSOLIDATION): Patients on Arms A or S are randomized to either Arms C or D. Patients on Arm B or S are randomized to either Arms E or F. Patients on Arms G or S are randomized to either Arms I or J. Patients on Arms H or S are randomized to Arms K or L. ARM C: Patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity. ARM D: Patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity. ARM E: Patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity. ARM F: Patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity. ARM I: Patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients continue oxaliplatin, leucovorin, 5-fluorouracil and nivolumab as outlined in Arm G for 2 years in the absence of disease progression or unacceptable toxicity. ARM J: Patients continue oxaliplatin, leucovorin, 5-fluorouracil, and nivolumab as outlined in Arm G for 2 years in the absence of disease progression or unacceptable toxicity. ARM K: Patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients continue oxaliplatin, capecitabine, and nivolumab as outlined in Arm H for 2 years in the absence of disease progression or unacceptable toxicity. ARM L: Patients continue oxaliplatin, capecitabine, and nivolumab as outlined in Arm H for 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for up to 5 years from study entry. Patients experiencing disease progression are followed up every 3 months in years 1-2, and then every 6 months for up to 5 years from study entry.
Interactive content above is from the official study record on the National Cancer Institute website, cancer.gov.
The ECOG-ACRIN Cancer Research Group designed this trial and is conducting it with funding from the National Cancer Institute through its National Clinical Trials Network.
